A citation-based method for searching scientific literature

Louisa R Hoes, Jade M van Berge Henegouwen, Hanneke van der Wijngaart, Laurien J Zeverijn, Daphne L van der Velden, Joris van de Haar, Paul Roepman, Wendy J de Leng, Anne M L Jansen, Erik van Werkhoven, Vincent van der Noort, Alwin D R Huitema, Eelke H Gort, Jan Willem B de Groot, Emile D Kerver, Derk Jan de Groot, Frans Erdkamp, Laurens V Beerepoot, Mathijs P Hendriks, Egbert F Smit, Winette T A van der Graaf, Carla M L van Herpen, Mariette Labots, Ann Hoeben, Hans Morreau, Martijn P Lolkema, Edwin Cuppen, Hans Gelderblom, Henk M W Verheul, Emile E Voest. Clin Cancer Res 2022
Times Cited: 4







List of co-cited articles
8 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
Robert C Doebele, Alexander Drilon, Luis Paz-Ares, Salvatore Siena, Alice T Shaw, Anna F Farago, Collin M Blakely, Takashi Seto, Byung Chul Cho, Diego Tosi,[...]. Lancet Oncol 2020
535
75

The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs.
D L van der Velden, L R Hoes, H van der Wijngaart, J M van Berge Henegouwen, E van Werkhoven, P Roepman, R L Schilsky, W W J de Leng, A D R Huitema, B Nuijen,[...]. Nature 2019
89
75

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.
Aurélien Marabelle, Marwan Fakih, Juanita Lopez, Manisha Shah, Ronnie Shapira-Frommer, Kazuhiko Nakagawa, Hyun Cheol Chung, Hedy L Kindler, Jose A Lopez-Martin, Wilson H Miller,[...]. Lancet Oncol 2020
699
50

Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.
Samuel A Wells, Sylvia L Asa, Henning Dralle, Rossella Elisei, Douglas B Evans, Robert F Gagel, Nancy Lee, Andreas Machens, Jeffrey F Moley, Furio Pacini,[...]. Thyroid 2015
988
50

Rationale and Design of the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
Pam K Mangat, Susan Halabi, Suanna S Bruinooge, Elizabeth Garrett-Mayer, Ajjai Alva, Katherine A Janeway, Philip J Stella, Emile Voest, Kathleen J Yost, Jane Perlmutter,[...]. JCO Precis Oncol 2018
67
50

Precision oncology based on omics data: The NCT Heidelberg experience.
Peter Horak, Barbara Klink, Christoph Heining, Stefan Gröschel, Barbara Hutter, Martina Fröhlich, Sebastian Uhrig, Daniel Hübschmann, Matthias Schlesner, Roland Eils,[...]. Int J Cancer 2017
87
50

Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers.
Peter Horak, Christoph Heining, Simon Kreutzfeldt, Barbara Hutter, Andreas Mock, Jennifer Hüllein, Martina Fröhlich, Sebastian Uhrig, Arne Jahn, Andreas Rump,[...]. Cancer Discov 2021
37
50

Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.
John D Hainsworth, Funda Meric-Bernstam, Charles Swanton, Herbert Hurwitz, David R Spigel, Christopher Sweeney, Howard Burris, Ron Bose, Bongin Yoo, Alisha Stein,[...]. J Clin Oncol 2018
255
50

Targeted Therapy for Advanced Thyroid Cancer: Kinase Inhibitors and Beyond.
Maria E Cabanillas, Mabel Ryder, Camilo Jimenez. Endocr Rev 2019
104
25

Efficacy of Selpercatinib in RET-Altered Thyroid Cancers.
Lori J Wirth, Eric Sherman, Bruce Robinson, Benjamin Solomon, Hyunseok Kang, Jochen Lorch, Francis Worden, Marcia Brose, Jyoti Patel, Sophie Leboulleux,[...]. N Engl J Med 2020
216
25

Early evolutionary divergence between papillary and anaplastic thyroid cancers.
J Capdevila, R Mayor, F M Mancuso, C Iglesias, G Caratù, I Matos, C Zafón, J Hernando, A Petit, P Nuciforo,[...]. Ann Oncol 2018
33
25

Novel Inhibitor-Based Therapies for Thyroid Cancer-An Update.
Maciej Ratajczak, Damian Gaweł, Marlena Godlewska. Int J Mol Sci 2021
10
25

Mutational profiling of poorly differentiated and anaplastic thyroid carcinoma by the use of targeted next-generation sequencing.
Huanli Duan, Yan Li, Peizhen Hu, Jie Gao, Jianming Ying, Wanni Xu, Danhui Zhao, Zhe Wang, Junyi Ye, Analyn Lizaso,[...]. Histopathology 2019
33
25

A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma.
Cristina Romei, Raffaele Ciampi, Rossella Elisei. Nat Rev Endocrinol 2016
175
25

Landscape of Microsatellite Instability Across 39 Cancer Types.
Russell Bonneville, Melanie A Krook, Esko A Kautto, Jharna Miya, Michele R Wing, Hui-Zi Chen, Julie W Reeser, Lianbo Yu, Sameek Roychowdhury. JCO Precis Oncol 2017
505
25


Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.
Vivek Subbiah, Robert J Kreitman, Zev A Wainberg, Jae Yong Cho, Jan H M Schellens, Jean Charles Soria, Patrick Y Wen, Christoph Zielinski, Maria E Cabanillas, Gladys Urbanowitz,[...]. J Clin Oncol 2018
385
25

Advances in Biomarker-Driven Targeted Therapies in Thyroid Cancer.
Prachi Mishra, Dipranjan Laha, Robert Grant, Naris Nilubol. Cancers (Basel) 2021
2
50

Progresses Toward Precision Medicine in RET-altered Solid Tumors.
Carmen Belli, Santosh Anand, Justin F Gainor, Frederique Penault-Llorca, Vivek Subbiah, Alexander Drilon, Fabrice Andrè, Giuseppe Curigliano. Clin Cancer Res 2020
17
25

Hobnail variant of papillary thyroid carcinoma: an institutional case series and molecular profile.
Carrie C Lubitz, Konstantinos P Economopoulos, Amanda C Pawlak, Kerry Lynch, Dora Dias-Santagata, William C Faquin, Peter M Sadow. Thyroid 2014
56
25

Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.
Alexander Drilon, Theodore W Laetsch, Shivaani Kummar, Steven G DuBois, Ulrik N Lassen, George D Demetri, Michael Nathenson, Robert C Doebele, Anna F Farago, Alberto S Pappo,[...]. N Engl J Med 2018
25

Papillary Thyroid Cancer-Aggressive Variants and Impact on Management: A Narrative Review.
Andrés Coca-Pelaz, Jatin P Shah, Juan C Hernandez-Prera, Ronald A Ghossein, Juan P Rodrigo, Dana M Hartl, Kerry D Olsen, Ashok R Shaha, Mark Zafereo, Carlos Suarez,[...]. Adv Ther 2020
37
25

Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden.
Zachary R Chalmers, Caitlin F Connelly, David Fabrizio, Laurie Gay, Siraj M Ali, Riley Ennis, Alexa Schrock, Brittany Campbell, Adam Shlien, Juliann Chmielecki,[...]. Genome Med 2017
25

Pre-Analytical Considerations for Successful Next-Generation Sequencing (NGS): Challenges and Opportunities for Formalin-Fixed and Paraffin-Embedded Tumor Tissue (FFPE) Samples.
Gladys Arreaza, Ping Qiu, Ling Pang, Andrew Albright, Lewis Z Hong, Matthew J Marton, Diane Levitan. Int J Mol Sci 2016
45
25


Targeted Therapies in Cancer: To Be or Not to Be, Selective.
Skye Montoya, Deborah Soong, Nina Nguyen, Maurizio Affer, Sailasya P Munamarty, Justin Taylor. Biomedicines 2021
4
25

ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research.
C Belli, F Penault-Llorca, M Ladanyi, N Normanno, J-Y Scoazec, L Lacroix, J S Reis-Filho, V Subbiah, J F Gainor, V Endris,[...]. Ann Oncol 2021
34
25

Molecular Genetics of Follicular-Derived Thyroid Cancer.
Elisabetta Macerola, Anello Marcello Poma, Paola Vignali, Alessio Basolo, Clara Ugolini, Liborio Torregrossa, Ferruccio Santini, Fulvio Basolo. Cancers (Basel) 2021
12
25

Remarkable Response to Ceritinib and Brigatinib in an Anaplastic Lymphoma Kinase-Rearranged Anaplastic Thyroid Carcinoma Previously Treated with Crizotinib.
Laura Leroy, Benjamin Bonhomme, Sylvestre Le Moulec, Isabelle Soubeyran, Antoine Italiano, Yann Godbert. Thyroid 2020
15
25

RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies.
Benjamin J Solomon, Lavinia Tan, Jessica J Lin, Stephen Q Wong, Sebastian Hollizeck, Kevin Ebata, Brian B Tuch, Satoshi Yoda, Justin F Gainor, Lecia V Sequist,[...]. J Thorac Oncol 2020
107
25

Novel Therapeutics in Radioactive Iodine-Resistant Thyroid Cancer.
Tanner Fullmer, Maria E Cabanillas, Mark Zafereo. Front Endocrinol (Lausanne) 2021
13
25

Comprehensive Analysis of the Transcriptional and Mutational Landscape of Follicular and Papillary Thyroid Cancers.
Seong-Keun Yoo, Seungbok Lee, Su-Jin Kim, Hyeon-Gun Jee, Byoung-Ae Kim, Hyesun Cho, Young Shin Song, Sun Wook Cho, Jae-Kyung Won, Jong-Yeon Shin,[...]. PLoS Genet 2016
182
25

Complete response in anaplastic lymphoma kinase-rearranged oncocytic thyroid cancer: A case report and review of literature.
Victoire de Salins, Gokoulakrichenane Loganadane, Charlotte Joly, Mukedaisi Abulizi, Maya Nourieh, Hélène Boussion, Yazid Belkacemi, Christophe Tournigand, Emmanuelle Kempf. World J Clin Oncol 2020
5
25

TERT Promoter Mutation Predicts Radioiodine-Refractory Character in Distant Metastatic Differentiated Thyroid Cancer.
Xue Yang, Jiao Li, Xiaoyi Li, Zhiyong Liang, Wen Gao, Jun Liang, Shujun Cheng, Yansong Lin. J Nucl Med 2017
52
25

ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research.
C Marchiò, M Scaltriti, M Ladanyi, A J Iafrate, F Bibeau, M Dietel, J F Hechtman, T Troiani, F López-Rios, J-Y Douillard,[...]. Ann Oncol 2019
163
25

Acquired Secondary RAS Mutation in BRAFV600E-Mutated Thyroid Cancer Patients Treated with BRAF Inhibitors.
Maria E Cabanillas, Ramona Dadu, Pryianka Iyer, Kacey B Wanland, Naifa L Busaidy, Anita Ying, Maria Gule-Monroe, Jennifer R Wang, Mark Zafereo, Marie-Claude Hofmann. Thyroid 2020
28
25

Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers.
Iñigo Landa, Tihana Ibrahimpasic, Laura Boucai, Rileen Sinha, Jeffrey A Knauf, Ronak H Shah, Snjezana Dogan, Julio C Ricarte-Filho, Gnana P Krishnamoorthy, Bin Xu,[...]. J Clin Invest 2016
574
25

Genetic Determinants for Prediction of Outcome of Patients with Papillary Thyroid Carcinoma.
Antónia Afonso Póvoa, Elisabete Teixeira, Maria Rosa Bella-Cueto, Rui Batista, Ana Pestana, Miguel Melo, Thalita Alves, Mafalda Pinto, Manuel Sobrinho-Simões, Jorge Maciel,[...]. Cancers (Basel) 2021
4
25

Targeted Therapy of Papillary Thyroid Cancer: A Comprehensive Genomic Analysis.
Daniel A Hescheler, Burkhard Riemann, Milan J M Hartmann, Maximilian Michel, Michael Faust, Christiane J Bruns, Hakan Alakus, Costanza Chiapponi. Front Endocrinol (Lausanne) 2021
2
50

Progress in Treating Advanced Thyroid Cancers in the Era of Targeted Therapy.
Carrie C Lubitz, Peter M Sadow, Gilbert H Daniels, Lori J Wirth. Thyroid 2021
6
25

Effects of tyrosine kinase inhibitors on thyroid function and thyroid hormone metabolism.
Alessio Basolo, Antonio Matrone, Rossella Elisei, Ferruccio Santini. Semin Cancer Biol 2022
9
25

Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers.
Nikita Pozdeyev, Laurie M Gay, Ethan S Sokol, Ryan Hartmaier, Kelsi E Deaver, Stephanie Davis, Jena D French, Pierre Vanden Borre, Daniel V LaBarbera, Aik-Choon Tan,[...]. Clin Cancer Res 2018
217
25

Next-generation sequencing in thyroid cancers: do targetable alterations lead to a therapeutic advantage?: A multicenter experience.
Assaf Moore, Yael Bar, Corinne Maurice-Dror, Inbar Finkel, Hadar Goldvaser, Elizabeth Dudnik, Daniel A Goldstein, Noa Gordon, Salem Billan, Orit Gutfeld,[...]. Medicine (Baltimore) 2021
4
25

Overcoming TKI resistance in fusion-driven NSCLC: new generation inhibitors and rationale for combination strategies.
Alessandro Russo, Andrés F Cardona, Christian Caglevic, Paolo Manca, Alejandro Ruiz-Patiño, Oscar Arrieta, Christian Rolfo. Transl Lung Cancer Res 2020
6
25

Improvement strategies for successful next-generation sequencing analysis of lung cancer.
Kei Kunimasa, Shingo Matsumoto, Kazumi Nishino, Harumi Nakamura, Hanako Kuhara, Motohiro Tamiya, Takako Inoue, Takahisa Kawamura, Hayato Kawachi, Kika Kuno,[...]. Future Oncol 2020
5
25

An impressive response with larotrectinib in a patient with a papillary thyroid carcinoma harboring an SQSTM1-NTRK1 fusion.
Sophie Bargas, Anne Mc Leer, Julie Mondet, Olivier Chabre, Mathieu Laramas. Eur J Endocrinol 2022
1
100

Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer.
Janice M Mehnert, Andrea Varga, Marcia S Brose, Rahul R Aggarwal, Chia-Chi Lin, Amy Prawira, Filippo de Braud, Kenji Tamura, Toshihiko Doi, Sarina A Piha-Paul,[...]. BMC Cancer 2019
85
25

High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden.
Ryma Benayed, Michael Offin, Kerry Mullaney, Purvil Sukhadia, Kelly Rios, Patrice Desmeules, Ryan Ptashkin, Helen Won, Jason Chang, Darragh Halpenny,[...]. Clin Cancer Res 2019
203
25

PD-1 Blockade in Anaplastic Thyroid Carcinoma.
Jaume Capdevila, Lori J Wirth, Thomas Ernst, Santiago Ponce Aix, Chia-Chi Lin, Rodryg Ramlau, Marcus O Butler, Jean-Pierre Delord, Hans Gelderblom, Paolo A Ascierto,[...]. J Clin Oncol 2020
92
25

Integrated Genomic Analysis of Hürthle Cell Cancer Reveals Oncogenic Drivers, Recurrent Mitochondrial Mutations, and Unique Chromosomal Landscapes.
Ian Ganly, Vladimir Makarov, Shyamprasad Deraje, YiYu Dong, Ed Reznik, Venkatraman Seshan, Gouri Nanjangud, Stephanie Eng, Promita Bose, Fengshen Kuo,[...]. Cancer Cell 2018
121
25


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.